These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2776594)

  • 1. Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer.
    Koshikawa T; Leyh H; Schenck U
    Diagn Cytopathol; 1989; 5(2):117-21. PubMed ID: 2776594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytological changes induced by intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.
    Takashi M; Schenck U; Koshikawa T; Nakashima N; Ohshima S
    Urol Int; 2000; 64(2):74-81. PubMed ID: 10810268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravesical mitomycin for superficial tumors of the bladder: difficulties of cystoscopic monitoring].
    Fourcade RO; Giuliano F
    Ann Urol (Paris); 1988; 22(6):404-6. PubMed ID: 3146942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer.
    Cant JD; Murphy WM; Soloway MS
    Cancer; 1986 Jun; 57(11):2119-22. PubMed ID: 3084057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of urothelial dysplasia in macroscopically normal mucosa in patients with bladder tumors. Results of a randomized study with and without intravesical mitomycin C in the prevention of recurrence].
    Maier U; Holzner JH
    Onkologie; 1985 Aug; 8(4):232-40. PubMed ID: 3937968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
    J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological changes due to intravesical instillation of mitomycin C.
    Castillo OA; Landerer E; Feria-Flores M; Vidal-Mora I; Franco C
    Arch Esp Urol; 2012 Jun; 65(5):578-82; discussion 582. PubMed ID: 22732786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
    Mobley WC; Loening SA; Narayana AS; Culp DA
    Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of intravesical mitomycin C in patients with multiple prior occurrences of superficial bladder cancer.
    Schwarzman MI; Johanson KE; Surya B; Brown J
    Urology; 1988 Oct; 32(4):335-8. PubMed ID: 3140465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitomycin-C induced improvement in superficial bladder tumors: a morphologic and immunohistochemical evaluation.
    Strobel SL; Tuttle SE; Wise HA; Sharma HM
    Urol Res; 1985; 13(2):51-4. PubMed ID: 3925608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor.
    Kim HH; Lee C
    J Urol; 1989 Jun; 141(6):1337-9; discussion 1339-40. PubMed ID: 2498532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical mitomycin C for carcinoma in situ of the urinary bladder.
    Hellsten S; Månsson W; Henrikson H; Idwall I; Lindholm K; Mikulowski P; Mårtensson S; Oldbring J
    Scand J Urol Nephrol; 1990; 24(1):35-8. PubMed ID: 2108491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
    Pavlotsky A; Eidelman A; Barak F; Alon H; Horn Y
    J Surg Oncol; 1989 May; 41(1):9-11. PubMed ID: 2497274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Local mitomycin-C therapy of infiltrating bladder cancer].
    Erdmann WD; Harzmann R; Flüchter SH; Bichler KH
    Fortschr Med; 1984 Aug; 102(29-30):767-71. PubMed ID: 6437950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary urinary cytodiagnosis of a bladder small-cell carcinoma.
    Rollins S; Schumann GB
    Diagn Cytopathol; 1991; 7(1):79-82. PubMed ID: 1851081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting mitomycin C in human plasma during intravesical therapy.
    Jauhiainen K
    Int Urol Nephrol; 1985; 17(2):155-8. PubMed ID: 3936816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
    Huland H; Otto U; Droese M; Klöppel G
    J Urol; 1984 Jul; 132(1):27-9. PubMed ID: 6427483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term observation after intravesical metaphylaxis with mitomycin C in patients with superficial bladder tumors.
    Maier U; Höbarth K
    Urology; 1991 May; 37(5):481-2. PubMed ID: 1902606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.